title: [Combined cytostatic-radiologic therapy of advanced malignant tumors in otorhinolaryngology. Experiences and results with over 100 patients].
abstract: For over ten years the therapy schedule of combined treatment (partial synchronisation) has been clinically tested and applied. Positive results are reported. The reasons for these positive results seem to be more the additive effects than the synchronisation. Despite some doubts concerning the effectivity of synchronisation, these so called partial synchronisation therapy has been applied since 1972 because of the encouraging own results and the positive results reported by other authors. 5 FU, Vincristine, Bleomycin and Adriamycin have been used as cytostatic drugs; the highly differentiated keratinizing squamous cell carcinomas should be treated with Bleomycin. Our report covers the results of over 100 patients with malignant ENT-tumors treated by the schedules. Most patients came with advanced inoperable tumors or recurrences after surgery and/or irradiation; the combined therapy with 5 FU Bleomycin and Adriamycin increased complications and side effects than radiotherapy alone. A recent trend is to use Bleomycin or Adriamycin as cytostatic drugs. The breakdown of survival rates according to the tumor localisation shows the best 5 year survival times of patients with laryngeal/hypopharyngeal carcinomas (advanced tumors respectively recurrences). This combined therapy leading to a surprising remission in a short time and to a prolongation of life with supportable feelings, seems to be an usefull supplement of therapeutical methods in advanced ENT-tumors.
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006801:Humans; D007822:Laryngeal Neoplasms / Q000628:therapy*; D008207:Lymphatic Metastasis; D009062:Mouth Neoplasms / Q000628:therapy*; D010610:Pharyngeal Neoplasms / Q000628:therapy*; D011879:Radiotherapy Dosage
chemical_list: D000970:Antineoplastic Agents
vernacular_title: Die zytostatisch-radiologische Kombinationstherapie fortgeschrittener maligner Tumoren im HNO-Bereich. Erfahrungen und Ergebnisse von über 100 Patienten.